BLLN
BillionToOne·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BLLN
Billiontoone, Inc.
A high-growth U.S.molecular diagnostics company,specializing in single-base-pair precision DNA detection technology,primarily focused on non-invasive prenatal testing and cancer liquid biopsy products
1035 O’Brien Drive
Menlo Park
CA 94025
--
BillionToOne, Inc., began operations as a Delaware corporation in 2016. The company has developed a revolutionary single-molecule next-generation sequencing (smNGS) platform capable of detecting and precisely quantifying gene targets with single-molecule sensitivity. At the heart of this innovation is its patented Quantitative Counting Template (QCT), which measures at the level of a single DNA molecule. This technology breaks through a key bottleneck in healthcare in detecting sparse but clinically significant disease signals in free DNA. BillionToOne's technology platform has been successfully applied to a range of groundbreaking prenatal and oncology products that provide actionable diagnostic information with only a simple blood sample.
Company Financials
EPS
BLLN has released its 2025 Q4 earnings. EPS was reported at 0.11, versus the expected 0.06, beating expectations. The chart below visualizes how BLLN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BLLN has released its 2025 Q4 earnings report, with revenue of 96.05M, reflecting a YoY change of 113.09%, and net profit of 5.98M, showing a YoY change of 152.08%. The Sankey diagram below clearly presents BLLN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
